Patient Self-Administered Intralesional Injections of Triamcinolone for Acne Vulgaris
The goal of this clinical trial is to test the safety of intralesional injections of triamcinolone self-administered into acne lesions via an injection assistance device. The main question\[s\] it aims to answer are: * is use of the injection assistance device safe? * is delivery of triamcinolone to acne lesions via the injection assistance device efficacious? Participants will self-inject low dose triamcinolone into acne lesions and track lesion response via photos and survey for 14 days following injection.
• Outpatient, male or female of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative UPT at Baseline.
• Diagnosed with facial acne vulgaris.
• At least one (1) identifiable inflammatory lesion that, in the opinion of the investigator, is clinically indicated for standard-of-care intralesional injection(s) of triamcinolone.
• Owner of smartphone with capacity for front-facing photography and app download from Apple App Store or Google Play.
• Able to follow study instructions and likely to comply with virtual follow-up requirements.
• In good general health as determined by medical history at the time of screening (Investigator discretion).
• Sign the IRB-approved ICF (including HIPAA authorization) prior to any study-related procedures being performed.